Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
Risk & Volatility
Neuphoria Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Profitability
This table compares Neuphoria Therapeutics and Abeona Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuphoria Therapeutics | N/A | -53.17% | -36.15% |
| Abeona Therapeutics | N/A | 71.94% | 44.09% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuphoria Therapeutics | $15.65 million | 1.40 | -$370,000.00 | ($4.88) | -0.84 |
| Abeona Therapeutics | $3.50 million | 82.99 | -$63.73 million | $1.23 | 4.36 |
Neuphoria Therapeutics has higher revenue and earnings than Abeona Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Neuphoria Therapeutics and Abeona Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuphoria Therapeutics | 2 | 0 | 2 | 0 | 2.00 |
| Abeona Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 414.71%. Abeona Therapeutics has a consensus target price of $20.00, indicating a potential upside of 273.13%. Given Neuphoria Therapeutics’ higher probable upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Abeona Therapeutics.
Institutional & Insider Ownership
15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Abeona Therapeutics beats Neuphoria Therapeutics on 10 of the 13 factors compared between the two stocks.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
About Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
